Merck’s Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) & Pifeltro (doravirine) Receives EU’s Approval for the Treatment of HIV-1 Infection

 Merck’s Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) & Pifeltro (doravirine) Receives EU’s Approval for the Treatment of HIV-1 Infection

Merck’s Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) & Pifeltro (doravirine) Receives EU’s Approval for the Treatment of HIV-1 Infection

Shots:

  • The approval is based on the results of P-III DRIVE-AHEAD and DRIVE-FORWARD trial assessing Delstrigo vs efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) & Pifeltro vs darunavir + ritonavir (DRV+r) + FTC/TDF or abacavir (ABC)/3TC respectively for a duration of 48/96 wks.
  • DRIVE-AHEAD and DRIVE-FORWARD results: suppression of HIV-1 RNA @ 48 wks. (84%, 83% vs 80%, 79%), suppression of HIV-1 RNA @ 96 wks. (76%, 72% vs 73%, 64%)
  • Delstrigo is qd fixed dose of doravirine (100 mg), lamivudine (3TC, 300 mg) and (TDF, 300 mg) & Pifeltro (doravirine, 100 mg) are non-nucleoside reverse transcriptase inhibitors (NNRTI) indicated for treatment of HIV-1 in adults

Click here to read full press release/ article | Ref: Merck | Image: Washington Times

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post